Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Exclusion Criteria

• •Patients with Philadelphia chromosome negative but BCR-ABL positive CML
• •Patients who used imatinib for 8 days or longer before study entry
• •Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells
• •Patients with impaired cardiac function
• •Cytologically confirmed CNS involvement
• •Severe or uncontrolled chronic medical condition
• •Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia
• •Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery